

# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	5	7.2	69.7	(22.5-162.7)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	3.2	157.3	(50.7-367.0)	Female	3	0.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	11	8.9	123.3	(61.5-220.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	43.3	90.1	(64.0-123.1)	Male	31	22.4	138.5	(94.1-196.6)
Female	16	16.5	97.1	(55.4-157.6)	Female	27	18.2	148.3	(97.7-215.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.4	108.2	(46.6-213.2)	Male	5	6.4	77.6	(25.0-181.0)
Female	7	6.4	108.6	(43.5-223.7)	Female	4	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	24	20.9	114.7	(73.5-170.7)
Female	139	155.9	89.2	(75.0-105.3)	Female	19	20.4	93.2	(56.1-145.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	6.2	nc	(nc-nc)	Male	9	15.3	59.0	(26.9-112.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	55	63.8	86.2	(64.9-112.2)	Female	18	16.9	106.5	(63.1-168.4)
Female	41	66.0	62.1	(44.6-84.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	12.1	49.7	(18.1-108.2)
Male	10	10.7	93.1	(44.6-171.3)	Female	11	14.1	77.9	(38.8-139.4)
Female	2	3.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	182	163.6	111.3	(95.7-128.7)
Male	3	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	4	10.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	7.2	111.3	(47.9-219.3)
Male	18	17.3	104.1	(61.7-164.6)	<b><u>Testis</u></b>				
Female	6	11.4	52.6	(19.2-114.5)	Male	2	3.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	6.9	nc	(nc-nc)	Male	5	4.3	117.4	(37.8-273.9)
Female	0	2.0	nc	(nc-nc)	Female	25	13.8	181.6	(117.5-268.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	14	12.9	108.7	(59.4-182.4)	Female	33	32.3	102.1	(70.3-143.4)
Female	10	11.2	89.2	(42.7-164.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	506	552.5	91.6	(83.8-99.9)
Male	7	8.4	82.9	(33.2-170.8)	Female	487	538.5	90.4	(82.6-98.8)
Female	4	3.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	50	79.5	62.9	(46.6-82.9)					
Female	57	76.0	75.0	(56.8-97.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

163

## Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	10.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	6	8.5	70.5	(25.8-153.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	4	10.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	6	8.5	70.5	(25.8-153.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

164

## Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	10	4.5	222.9	(106.7-409.9)
Female	0	2.5	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	38	28.3	134.2	(95.0-184.2)	Female	1	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	11.7	110.7	(58.9-189.3)	Female	2	3.0	nc	(nc-nc)
Female	14	9.6	145.3	(79.4-243.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	2.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	33	30.8	107.1	(73.7-150.4)
Male	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.0	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	3.3	182.6	(66.7-397.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.6	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	96	105.0	91.5	(74.1-111.7)
Male	1	1.6	nc	(nc-nc)	Female	91	91.9	99.0	(79.7-121.5)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	14.7	40.9	(14.9-89.0)					
Female	10	12.3	81.2	(38.9-149.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

165

## Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	8.5	93.9	(40.4-185.0)	Male	7	5.0	139.8	(56.0-288.1)
Female	4	3.0	nc	(nc-nc)	Female	11	4.1	267.2	(133.2-478.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	1.8	341.7	(124.8-743.8)	Male	3	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.5	110.1	(35.5-257.0)
Female	33	32.7	100.8	(69.4-141.6)	Female	3	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	12.9	131.9	(76.8-211.2)	Female	3	3.5	nc	(nc-nc)
Female	10	12.0	83.2	(39.8-152.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	2.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	32	33.8	94.8	(64.8-133.8)
Male	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.3	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.8	nc	(nc-nc)	Female	5	6.7	74.7	(24.1-174.4)
Female	2	2.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	112	115.2	97.2	(80.0-117.0)
Male	1	1.8	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	12	15.9	75.3	(38.9-131.5)					

Female	9	14.4	62.7	(28.6-119.0)	Female	103	108.2	95.2	(77.7-115.5)
--------	---	------	------	--------------	--------	-----	-------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

166

## Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.7	87.5	(52.7-136.7)	Male	14	11.3	123.8	(67.6-207.7)
Female	9	8.1	111.2	(50.8-211.2)	Female	11	9.1	121.1	(60.4-216.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.7	133.7	(43.1-312.0)	Male	2	3.2	nc	(nc-nc)
Female	5	3.2	155.5	(50.1-363.0)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	10	10.5	94.9	(45.4-174.6)
Female	81	77.3	104.8	(83.2-130.3)	Female	15	10.1	148.7	(83.2-245.3)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	2	7.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	32.1	74.8	(47.9-111.2)	Female	10	8.4	118.9	(56.9-218.7)
Female	25	32.8	76.2	(49.3-112.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.1	82.1	(26.5-191.7)
Male	6	5.4	110.8	(40.5-241.1)	Female	6	7.0	86.3	(31.5-187.7)
Female	1	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	90	82.7	108.9	(87.5-133.8)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	6	5.5	109.4	(39.9-238.1)
<u>Kidney &amp; Renal Pelvis</u>					Female	0	3.6	nc	(nc-nc)
Male	4	8.7	nc	(nc-nc)	<u>Testis</u>				
Female	9	5.6	160.4	(73.2-304.5)	Male	5	1.8	279.1	(89.9-651.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.5	92.5	(33.8-201.3)	Female	21	16.1	130.6	(80.8-199.6)
Female	6	5.6	107.4	(39.2-233.8)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	5	4.3	116.8	(37.6-272.6)					
Female	0	1.6	nc	(nc-nc)					

**Lung and Bronchus**

Male	20	39.6	50.5	(30.8-78.0)
Female	30	37.0	81.2	(54.7-115.9)

**All Sites / Types**

Male	243	278.3	87.3	(76.7-99.0)
Female	260	266.6	97.5	(86.0-110.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

167

**Lowell**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	97	82.1	118.1	(95.8-144.1)	Male	19	50.4	37.7	(22.7-58.9)
Female	28	34.1	82.2	(54.6-118.8)	Female	20	45.6	43.9	(26.8-67.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	18.9	79.4	(44.4-131.0)	Male	11	12.7	86.9	(43.3-155.5)
Female	16	16.1	99.1	(56.6-161.0)	Female	13	10.8	120.5	(64.1-206.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	52	45.7	113.7	(84.9-149.2)
Female	288	341.1	84.4	(75.0-94.8)	Female	49	44.8	109.4	(80.9-144.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	25	16.5	151.6	(98.1-223.8)	Male	65	32.8	198.3	(153.0-252.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	145	124.5	116.4	(98.2-137.0)	Female	38	37.3	102.0	(72.2-140.0)
Female	135	135.3	99.8	(83.7-118.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	16	23.5	68.1	(38.9-110.6)
Male	24	21.4	112.3	(71.9-167.1)	Female	34	28.9	117.7	(81.5-164.5)
Female	8	6.6	121.0	(52.1-238.5)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	278	325.9	85.3	(75.6-96.0)
Male	8	9.4	85.4	(36.8-168.4)	<b><u>Stomach</u></b>				
Female	9	7.9	114.0	(52.0-216.4)	Male	17	21.2	80.1	(46.6-128.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	15	14.7	102.3	(57.2-168.8)
Male	36	36.4	98.8	(69.2-136.8)	<b><u>Testis</u></b>				
Female	29	24.8	116.8	(78.2-167.8)	Male	6	17.6	34.0	(12.4-74.0)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	27	14.0	193.3	(127.4-281.3)	Male	5	11.9	42.2	(13.6-98.4)
Female	6	4.2	141.7	(51.7-308.5)	Female	39	40.2	97.0	(68.9-132.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	27	29.1	92.8	(61.1-135.0)					
Female	35	25.8	135.8	(94.5-188.8)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									

Male	30	17.6	170.5	(115.0-243.4)					
Female	7	6.9	101.4	(40.6-208.8)	Female	71	69.7	101.9 (79.6-128.6)	
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	176	154.5	113.9	(97.7-132.0)	Male	1141	1132.7	100.7 (95.0-106.8)	
Female	184	160.1	115.0	(98.9-132.8)	Female	1166	1179.0	98.9 (93.3-104.7)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

168  
**Ludlow**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	24.9	68.3	(39.8-109.3)	Male	10	14.2	70.6	(33.8-129.9)
Female	5	9.1	55.1	(17.7-128.5)	Female	4	10.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.8	145.2	(58.2-299.1)	Male	5	3.8	132.2	(42.6-308.6)
Female	4	3.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	8	13.0	61.7	(26.6-121.6)
Female	95	89.2	106.5	(86.1-130.1)	Female	14	11.6	120.5	(65.8-202.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.9	nc	(nc-nc)	Male	6	9.5	63.1	(23.0-137.3)
					Female	5	4.4	114.4	(36.9-267.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	27	37.4	72.3	(47.6-105.2)	Female	10	9.6	103.9	(49.7-191.0)
Female	34	35.5	95.9	(66.4-134.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	7.1	84.8	(31.0-184.6)
Male	4	6.4	nc	(nc-nc)	Female	6	7.7	78.3	(28.6-170.4)
Female	1	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	95	98.8	96.1	(77.8-117.5)
Male	2	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	6	6.3	94.7	(34.6-206.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.7	nc	(nc-nc)
Male	15	10.6	141.2	(79.0-232.9)	<b><u>Testis</u></b>				
Female	4	6.5	nc	(nc-nc)	Male	5	3.8	131.5	(42.4-306.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	4.2	nc	(nc-nc)	Male	7	3.1	227.6	(91.2-469.0)
Female	0	1.1	nc	(nc-nc)					
<b><u>Leukemia</u></b>									
Male	11	7.9	139.1	(69.3-248.8)					

Female	2	6.3	nc	(nc-nc)	Female	8	8.9	89.9	(38.7-177.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	5.1	nc	(nc-nc)	Female	20	18.6	107.7	(65.8-166.4)
Female	1	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male	300	333.9	89.8	(80.0-100.6)
Male	46	46.9	98.1	(71.8-130.9)	Female	261	305.6	85.4	(75.4-96.4)
Female	24	43.7	54.9	(35.2-81.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

169

## Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	10.3	67.9	(27.2-140.0)	Male	5	6.1	82.1	(26.5-191.6)
Female	4	3.4	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
Female	33	38.5	85.6	(58.9-120.3)	Female	6	4.5	134.2	(49.0-292.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	15.7	108.3	(63.0-173.4)	Female	2	4.1	nc	(nc-nc)
Female	12	13.1	91.7	(47.3-160.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	3.0	nc	(nc-nc)
Male	5	2.7	182.9	(58.9-426.7)	Female	4	2.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	38	41.7	91.1	(64.5-125.0)
Male	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.4	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>									
Male	2	1.8	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

**Leukemia**

Male	5	3.3	149.5	(48.2-348.8)
Female	3	2.4	nc	(nc-nc)

**Liver and Intrahepatic Bile Ducts**

Male	3	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

**Lung and Bronchus**

Male	20	19.5	102.7	(62.7-158.7)
Female	16	16.5	96.9	(55.3-157.3)

**Thyroid**

Male	0	1.3	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)

**Uteri Corpus and Uterus, NOS**

Female	5	8.0	62.8	(20.3-146.7)
--------	---	-----	------	--------------

**All Sites / Types**

Male	125	140.8	88.8	(73.9-105.8)
Female	108	123.8	87.3	(71.6-105.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

170

**Lynn**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b>Bladder, Urinary</b>					<b>Melanoma of Skin</b>				
Male	99	83.4	118.7	(96.4-144.5)	Male	38	47.9	79.4	(56.2-109.0)
Female	33	32.4	101.7	(70.0-142.8)	Female	23	41.9	54.8	(34.8-82.3)
<b>Brain and Other Nervous System</b>					<b>Multiple Myeloma</b>				
Male	19	17.4	109.2	(65.7-170.6)	Male	17	12.7	134.3	(78.2-215.1)
Female	20	14.9	134.2	(81.9-207.3)	Female	13	10.3	126.5	(67.3-216.4)
<b>Breast</b>					<b>Non-Hodgkin Lymphoma</b>				
Male	5	2.5	199.6	(64.3-465.8)	Male	56	44.1	127.1	(96.0-165.0)
Female	285	323.7	88.0	(78.1-98.9)	Female	45	42.2	106.7	(77.8-142.8)
<b>Cervix Uteri</b>					<b>Oral Cavity &amp; Pharynx</b>				
Female	22	15.1	146.1	(91.5-221.2)	Male	42	31.4	134.0	(96.5-181.1)
Female					Female	17	16.0	106.4	(61.9-170.4)
<b>Colon / Rectum</b>					<b>Ovary</b>				
Male	147	124.8	117.7	(99.5-138.4)	Female	26	35.2	73.9	(48.3-108.3)
Female	130	128.6	101.1	(84.5-120.1)	<b>Pancreas</b>				
<b>Esophagus</b>					Male	26	23.5	110.5	(72.2-161.9)
Male	30	21.1	142.0	(95.8-202.8)	Female	45	27.5	163.5	(119.3-218.8)
Female	6	6.3	95.1	(34.7-207.1)	<b>Prostate</b>				
<b>Hodgkin Lymphoma</b>					Male	289	319.4	90.5	(80.3-101.5)
Male	10	7.8	128.2	(61.4-235.9)	<b>Stomach</b>				
Female	10	6.7	148.5	(71.1-273.2)	Male	36	21.4	168.4	(118.0-233.2)
<b>Kidney &amp; Renal Pelvis</b>					Female	18	13.9	130.0	(77.0-205.4)
Male	32	35.2	90.8	(62.1-128.2)	<b>Testis</b>				
Female	35	23.6	148.6	(103.5-206.6)					
<b>Larynx</b>									

Male	20	13.7	146.2	(89.3-225.8)	Male	9	14.0	64.4	(29.4-122.3)
Female	11	4.0	272.0	(135.6-486.6)					
<b><u>Leukemia</u></b>					<b><u>Thyroid</u></b>				
Male	39	28.0	139.4	(99.1-190.5)	Male	11	10.5	104.7	(52.2-187.3)
Female	34	24.1	141.3	(97.9-197.5)	Female	30	36.1	83.2	(56.1-118.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	28	17.1	164.1	(109.0-237.1)	Female	64	66.5	96.2	(74.1-122.8)
Female	8	6.6	122.1	(52.6-240.6)					
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	207	154.6	133.9	(116.3-153.5)	Male	1246	1110.2	112.2	(106.1-118.6)
Female	193	153.0	126.2	(109.0-145.3)	Female	1167	1114.0	104.8	(98.8-110.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## 171 Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	16.9	100.3	(58.4-160.6)	Male	9	8.8	101.7	(46.4-193.1)
Female	10	5.4	184.3	(88.2-338.9)	Female	9	6.4	139.6	(63.7-265.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	4	8.2	nc	(nc-nc)
Female	61	55.1	110.7	(84.7-142.2)	Female	9	6.9	130.1	(59.4-247.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
					Female	6	2.7	226.3	(82.6-492.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	30	25.1	119.3	(80.5-170.3)	Female	5	5.9	84.8	(27.3-197.9)
Female	18	21.2	84.9	(50.3-134.3)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.3	140.5	(51.3-305.9)	Male	5	4.8	104.7	(33.7-244.3)
Female	0	1.1	nc	(nc-nc)	Female	5	4.6	109.5	(35.3-255.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	81	65.7	123.3	(97.9-153.2)
Female	0	0.8	nc	(nc-nc)					
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Stomach</u></b>				
Male	6	6.9	87.0	(31.8-189.4)	Male	4	4.3	nc	(nc-nc)

Female	2	4.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male	2	1.7	nc	(nc-nc)
Male	6	5.1	118.1	(43.1-257.1)	Female	3	5.2	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female	7	11.6	60.2	(24.1-124.0)
Male	1	3.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	236	219.4	107.6	(94.3-122.2)
<b><u>Lung and Bronchus</u></b>					Female	187	184.9	101.1	(87.2-116.7)
Male	23	31.5	73.0	(46.3-109.6)					
Female	21	26.3	79.8	(49.4-122.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

172

## Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	56.8	100.3	(76.0-130.0)	Male	19	32.6	58.2	(35.0-91.0)
Female	23	22.5	102.0	(64.7-153.1)	Female	22	28.9	76.1	(47.7-115.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	11.2	107.0	(55.2-187.0)	Male	7	8.6	81.4	(32.6-167.6)
Female	9	9.8	91.7	(41.9-174.2)	Female	5	7.1	70.3	(22.6-164.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	26	29.8	87.4	(57.1-128.0)
Female	210	221.1	95.0	(82.6-108.7)	Female	30	29.1	103.2	(69.6-147.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	14	10.3	135.5	(74.0-227.4)	Male	21	21.1	99.3	(61.5-151.9)
<b><u>Colon / Rectum</u></b>					Female	9	11.0	81.9	(37.4-155.4)
Male	101	84.8	119.1	(97.0-144.8)	<b><u>Ovary</u></b>				
Female	109	89.1	122.3	(100.4-147.5)	Female	23	24.0	95.6	(60.6-143.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	14.4	76.6	(38.2-137.1)	Male	22	16.0	137.7	(86.3-208.6)
Female	7	4.4	159.8	(64.0-329.3)	Female	13	19.1	68.1	(36.2-116.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	192	220.6	87.1	(75.2-100.3)
Female	4	4.4	nc	(nc-nc)					

**Kidney & Renal Pelvis**

Male	18	23.9	75.4	(44.7-119.2)
Female	14	16.1	87.0	(47.5-145.9)

**Larynx**

Male	6	9.3	64.2	(23.4-139.8)
Female	2	2.8	nc	(nc-nc)

**Leukemia**

Male	11	18.4	59.9	(29.9-107.1)
Female	16	16.0	99.7	(56.9-161.9)

**Liver and Intrahepatic Bile Ducts**

Male	14	11.5	121.4	(66.3-203.8)
Female	5	4.5	110.1	(35.5-256.8)

**Lung and Bronchus**

Male	133	105.7	125.8	(105.3-149.1)
Female	101	105.9	95.4	(77.7-115.9)

**Stomach**

Male	16	14.5	110.3	(63.0-179.1)
Female	23	9.6	238.8	(151.3-358.3)

**Testis**

Male	3	9.9	nc	(nc-nc)
------	---	-----	----	---------

**Thyroid**

Male	9	7.2	124.6	(56.9-236.6)
Female	34	24.6	138.0	(95.5-192.8)

**Uteri Corpus and Uterus, NOS**

Female	37	45.6	81.1	(57.1-111.8)
--------	----	------	------	--------------

**All Sites / Types**

Male	740	756.8	97.8	(90.9-105.1)
Female	776	765.0	101.4	(94.4-108.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

173

**Manchester**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	7.1	70.1	(22.6-163.5)	Male	2	3.9	nc	(nc-nc)
Female	6	2.5	238.5	(87.1-519.2)	Female	4	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	43	26.2	164.1	(118.7-221.0)	Female	3	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	10.7	111.7	(57.6-195.1)	Female	2	2.8	nc	(nc-nc)
Female	4	9.8	nc	(nc-nc)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				

Male	0	0.4	nc	(nc-nc)	Male	32	29.6	108.2	(74.0-152.8)
Female	0	0.4	nc	(nc-nc)					
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Stomach</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<b><u>Leukemia</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	1.5	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	13.6	59.0	(25.4-116.2)	Male	90	95.8	93.9	(75.5-115.5)
Female	8	12.1	66.0	(28.4-130.0)	Female	96	86.8	110.6	(89.6-135.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

174

## Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	13.8	123.5	(71.9-197.7)	Male	15	9.9	152.2	(85.1-251.1)
Female	10	4.8	206.5	(98.8-379.7)	Female	11	8.9	123.0	(61.3-220.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.9	nc	(nc-nc)	Male	5	2.2	224.0	(72.2-522.7)
Female	4	3.1	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	8.6	81.0	(32.4-166.8)
Female	51	63.3	80.6	(60.0-105.9)	Female	5	7.1	70.4	(22.7-164.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.7	135.6	(43.7-316.5)	Male	7	6.5	107.8	(43.2-222.2)
					Female	4	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	28	21.7	129.0	(85.7-186.5)	Female	5	6.6	76.1	(24.5-177.6)
Female	18	19.4	92.9	(55.0-146.8)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	3.8	289.2	(144.1-517.4)	Male	2	4.1	nc	(nc-nc)

Female	0	0.9	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b>Hodgkin Lymphoma</b>					<b>Prostate</b>				
Male	1	1.9	nc	(nc-nc)	Male	49	55.8	87.8	(64.9-116.1)
Female	5	1.6	321.7	(103.7-750.7)	<b>Stomach</b>				
<b>Kidney &amp; Renal Pelvis</b>					<b>Testis</b>				
Male	6	6.9	86.4	(31.5-188.0)	Male	4	3.7	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b>Larynx</b>					<b>Thyroid</b>				
Male	1	2.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	10	9.2	108.4	(51.9-199.3)
<b>Leukemia</b>					<b>Uteri Corpus and Uterus, NOS</b>				
Male	4	5.4	nc	(nc-nc)	Female	10	12.2	81.9	(39.2-150.6)
Female	4	4.3	nc	(nc-nc)	<b>All Sites / Types</b>				
<b>Liver and Intrahepatic Bile Ducts</b>					Male	197	201.6	97.7	(84.5-112.4)
Male	1	3.4	nc	(nc-nc)	Female	197	198.9	99.0	(85.7-113.9)
Female	3	1.0	nc	(nc-nc)					
<b>Lung and Bronchus</b>									
Male	16	26.1	61.3	(35.0-99.6)					
Female	24	23.6	101.9	(65.3-151.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

175

## Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b>Bladder, Urinary</b>					<b>Melanoma of Skin</b>				
Male	36	26.2	137.2	(96.1-189.9)	Male	39	14.3	272.8	(193.9-372.9)
Female	11	9.2	119.2	(59.4-213.4)	Female	23	11.6	198.3	(125.7-297.6)
<b>Brain and Other Nervous System</b>					<b>Multiple Myeloma</b>				
Male	8	4.8	167.2	(72.0-329.4)	Male	4	4.0	nc	(nc-nc)
Female	5	4.0	125.4	(40.4-292.6)	Female	1	2.9	nc	(nc-nc)
<b>Breast</b>					<b>Non-Hodgkin Lymphoma</b>				
Male	1	0.8	nc	(nc-nc)	Male	17	13.1	129.3	(75.3-207.1)
Female	128	96.6	132.5	(110.6-157.6)	Female	12	11.9	101.0	(52.1-176.5)
<b>Cervix Uteri</b>					<b>Oral Cavity &amp; Pharynx</b>				
Female	5	4.2	119.3	(38.4-278.3)	Male	5	10.0	50.0	(16.1-116.6)
<b>Colon / Rectum</b>					<b>Ovary</b>				
Male	49	39.3	124.6	(92.2-164.8)	Female	4	4.6	nc	(nc-nc)
Female	37	36.5	101.3	(71.3-139.6)	Female	8	10.3	77.7	(33.4-153.0)

**Esophagus**

Male	4	6.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)

**Hodgkin Lymphoma**

Male	1	1.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)

**Kidney & Renal Pelvis**

Male	10	11.1	90.4	(43.3-166.3)
Female	5	6.8	73.6	(23.7-171.7)

**Larynx**

Male	4	4.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)

**Leukemia**

Male	11	8.0	136.7	(68.1-244.6)
Female	4	6.5	nc	(nc-nc)

**Liver and Intrahepatic Bile Ducts**

Male	5	5.4	92.5	(29.8-215.8)
Female	0	1.9	nc	(nc-nc)

**Lung and Bronchus**

Male	37	49.1	75.4	(53.1-104.0)
Female	45	44.1	102.0	(74.4-136.5)

**Pancreas**

Male	11	7.5	147.2	(73.4-263.4)
Female	8	7.8	102.6	(44.2-202.3)

**Prostate**

Male	121	104.3	116.0	(96.2-138.6)
------	-----	-------	-------	--------------

**Stomach**

Male	2	6.6	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)

**Testis**

Male	2	2.6	nc	(nc-nc)
------	---	-----	----	---------

**Thyroid**

Male	3	2.9	nc	(nc-nc)
Female	5	9.6	52.0	(16.7-121.2)

**Uteri Corpus and Uterus, NOS**

Female	14	20.1	69.7	(38.1-116.9)
--------	----	------	------	--------------

**All Sites / Types**

Male	401	346.9	115.6	(104.5-127.5)
Female	347	320.9	108.1	(97.1-120.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

176

**Marion**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.6	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	5	3.0	165.7	(53.4-386.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	22	25.6	85.9	(53.8-130.1)	Female	4	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
					Female	2	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				

Male	6	11.2	53.5	(19.5-116.4)					
Female	12	10.3	116.1	(59.9-202.8)	Female	2	2.8	nc (nc-nc)	
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.1	nc (nc-nc)	
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc (nc-nc)	
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	24	29.3	82.0 (52.5-122.0)	
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc (nc-nc)	
Male	4	3.1	nc	(nc-nc)	Female	1	1.1	nc (nc-nc)	
Female	2	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc (nc-nc)	
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	0.8	nc (nc-nc)	
<b><u>Leukemia</u></b>					Female	2	2.4	nc (nc-nc)	
Male	0	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.8	nc	(nc-nc)	Female	11	5.4	202.7 (101.0-362.6)	
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	76	97.7	77.8 (61.3-97.3)	
Female	0	0.5	nc	(nc-nc)	Female	87	87.3	99.7 (79.8-123.0)	
<b><u>Lung and Bronchus</u></b>									
Male	12	14.0	85.6	(44.2-149.5)					
Female	7	12.3	56.8	(22.7-116.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

177

## Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	34.6	75.2	(49.1-110.2)	Male	13	21.0	61.9	(33.0-105.9)
Female	10	13.3	75.4	(36.1-138.6)	Female	15	18.0	83.4	(46.6-137.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	7.4	135.2	(64.7-248.6)	Male	6	5.4	111.9	(40.9-243.6)
Female	7	6.1	114.0	(45.7-234.8)	Female	5	4.2	119.9	(38.6-279.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	12	18.9	63.5	(32.7-110.8)
Female	148	138.0	107.2	(90.7-126.0)	Female	17	17.4	97.9	(57.0-156.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
					Male	17	13.9	122.0	(71.0-195.3)

Female	3	6.7	nc	(nc-nc)	Female	11	6.7	164.4	(82.0-294.2)
<b>Colon / Rectum</b>					<b>Ovary</b>				
Male	48	52.6	91.3	(67.3-121.0)	Female	15	14.8	101.1	(56.6-166.8)
Female	46	52.7	87.3	(63.9-116.5)	<b>Pancreas</b>				
<b>Esophagus</b>					Male	5	9.9	50.4	(16.2-117.5)
Male	6	9.0	66.5	(24.3-144.7)	Female	13	11.2	116.0	(61.7-198.3)
Female	4	2.6	nc	(nc-nc)	<b>Prostate</b>				
<b>Hodgkin Lymphoma</b>					Male	126	137.2	91.8	(76.5-109.3)
Male	4	3.4	nc	(nc-nc)	<b>Stomach</b>				
Female	3	2.7	nc	(nc-nc)	Male	7	9.0	78.1	(31.3-160.9)
<b>Kidney &amp; Renal Pelvis</b>					Female	8	5.7	140.3	(60.4-276.5)
Male	16	15.4	104.2	(59.5-169.3)	<b>Testis</b>				
Female	10	9.7	102.9	(49.2-189.2)	Male	6	6.4	93.2	(34.0-202.8)
<b>Larynx</b>					<b>Thyroid</b>				
Male	6	5.9	101.5	(37.1-220.9)	Male	7	4.8	144.4	(57.8-297.5)
Female	1	1.7	nc	(nc-nc)	Female	25	15.9	157.3	(101.8-232.2)
<b>Leukemia</b>					<b>Uteri Corpus and Uterus, NOS</b>				
Male	10	11.6	85.9	(41.1-158.0)	Female	27	28.3	95.4	(62.9-138.9)
Female	10	9.8	102.3	(49.0-188.2)	<b>All Sites / Types</b>				
<b>Liver and Intrahepatic Bile Ducts</b>					Male	435	473.2	91.9	(83.5-101.0)
Male	10	7.4	134.7	(64.5-247.7)	Female	459	465.6	98.6	(89.8-108.0)
Female	1	2.7	nc	(nc-nc)					
<b>Lung and Bronchus</b>									
Male	72	64.7	111.2	(87.0-140.0)					
Female	49	62.3	78.7	(58.2-104.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

178

## Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b>Bladder, Urinary</b>					<b>Melanoma of Skin</b>				
Male	28	22.0	127.3	(84.5-183.9)	Male	21	13.8	152.3	(94.2-232.8)
Female	12	7.7	156.5	(80.8-273.4)	Female	16	11.6	137.8	(78.7-223.8)
<b>Brain and Other Nervous System</b>					<b>Multiple Myeloma</b>				
Male	12	5.0	240.8	(124.3-420.7)	Male	7	3.5	202.0	(80.9-416.1)
Female	4	4.0	nc	(nc-nc)	Female	5	2.4	204.4	(65.9-477.0)
<b>Breast</b>					<b>Non-Hodgkin Lymphoma</b>				
Male	0	0.7	nc	(nc-nc)	Male	12	12.3	97.9	(50.5-171.0)
Female	97	93.0	104.3	(84.6-127.3)	Female	7	10.4	67.0	(26.8-138.1)

Cervix Uteri

Female	1	4.5	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	45	34.0	132.3	(96.5-177.1)
------	----	------	-------	--------------

Female	29	29.6	97.9	(65.6-140.6)
--------	----	------	------	--------------

Esophagus

Male	7	6.0	115.8	(46.4-238.6)
------	---	-----	-------	--------------

Female	1	1.5	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	2	2.0	nc	(nc-nc)
------	---	-----	----	---------

Female	2	1.7	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	12	10.4	115.1	(59.4-201.1)
------	----	------	-------	--------------

Female	2	6.2	nc	(nc-nc)
--------	---	-----	----	---------

Larynx

Male	3	4.0	nc	(nc-nc)
------	---	-----	----	---------

Female	0	1.1	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	6	7.5	79.7	(29.1-173.5)
------	---	-----	------	--------------

Female	7	5.8	120.6	(48.3-248.6)
--------	---	-----	-------	--------------

Liver and Intrahepatic Bile Ducts

Male	3	5.1	nc	(nc-nc)
------	---	-----	----	---------

Female	1	1.6	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	47	42.3	111.2	(81.7-147.8)
------	----	------	-------	--------------

Female	43	38.4	112.0	(81.1-150.9)
--------	----	------	-------	--------------

Oral Cavity & Pharynx

Male	12	9.8	122.7	(63.3-214.4)
------	----	-----	-------	--------------

Female	3	4.2	nc	(nc-nc)
--------	---	-----	----	---------

Ovary

Female	12	9.7	123.5	(63.7-215.8)
--------	----	-----	-------	--------------

Pancreas

Male	7	6.5	107.8	(43.2-222.1)
------	---	-----	-------	--------------

Female	4	6.3	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	134	94.2	142.2	(119.1-168.4)
------	-----	------	-------	---------------

Stomach

Male	6	5.7	105.8	(38.6-230.2)
------	---	-----	-------	--------------

Female	4	3.1	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	2	3.6	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	3	3.2	nc	(nc-nc)
------	---	-----	----	---------

Female	14	10.8	129.9	(71.0-218.0)
--------	----	------	-------	--------------

Uteri Corpus and Uterus, NOS

Female	31	19.4	160.2	(108.8-227.3)
--------	----	------	-------	---------------

All Sites / Types

Male	400	312.9	127.8	(115.6-141.0)
------	-----	-------	-------	---------------

Female	311	293.3	106.0	(94.6-118.5)
--------	-----	-------	-------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

179

**Mashpee**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	19.6	147.8	(99.0-212.3)	Male	10	10.0	100.3	(48.0-184.5)
Female	5	6.5	76.5	(24.6-178.5)	Female	10	7.7	129.4	(62.0-238.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	1	0.6	nc	(nc-nc)	Male	15	9.3	160.8	(89.9-265.2)
Female	97	63.6	152.5	(123.7-186.1)	Female	7	8.2	85.6	(34.3-176.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.7	nc	(nc-nc)	Male	5	6.6	75.3	(24.3-175.8)
<b><u>Colon / Rectum</u></b>					Female	2	3.1	nc	(nc-nc)
Male	36	28.7	125.4	(87.8-173.6)	<b><u>Ovary</u></b>				
Female	23	24.9	92.5	(58.6-138.8)	Female	5	6.9	72.9	(23.5-170.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.8	123.8	(45.2-269.4)	Male	5	5.4	91.9	(29.6-214.5)
Female	3	1.3	nc	(nc-nc)	Female	6	5.4	110.1	(40.2-239.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	111	76.2	145.7	(119.8-175.4)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.9	102.6	(33.1-239.4)
Male	11	7.8	141.9	(70.7-253.9)	Female	4	2.6	nc	(nc-nc)
Female	6	4.7	127.7	(46.6-278.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	5	3.1	159.3	(51.3-371.8)	<b><u>Thyroid</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	6.2	96.8	(35.3-210.6)
Male	6	5.8	103.7	(37.9-225.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	4.4	228.2	(109.2-419.6)	Female	17	13.5	126.1	(73.4-201.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	321	251.7	127.5	(114.0-142.3)
Female	0	1.3	nc	(nc-nc)	Female	250	217.6	114.9	(101.1-130.0)
<b><u>Lung and Bronchus</u></b>									
Male	42	36.7	114.4	(82.4-154.6)					
Female	29	31.8	91.3	(61.2-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

180

## Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	8.7	68.8	(25.1-149.8)	Male	9	4.7	192.4	(87.8-365.2)
Female	2	3.0	nc	(nc-nc)	Female	9	3.6	246.9	(112.7-468.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)

Female	1	1.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b>Breast</b>					<b>Non-Hodgkin Lymphoma</b>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	33	30.9	106.6	(73.4-149.8)	Female	3	3.9	nc	(nc-nc)
<b>Cervix Uteri</b>					<b>Oral Cavity &amp; Pharynx</b>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<b>Colon / Rectum</b>					Female	0	1.5	nc	(nc-nc)
Male	15	13.0	115.7	(64.7-190.8)	<b>Ovary</b>				
Female	13	11.9	109.0	(58.0-186.5)	Female	2	3.3	nc	(nc-nc)
<b>Esophagus</b>					<b>Pancreas</b>				
Male	1	2.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b>Hodgkin Lymphoma</b>					<b>Prostate</b>				
Male	0	0.5	nc	(nc-nc)	Male	26	35.2	73.8	(48.2-108.1)
Female	1	0.4	nc	(nc-nc)	<b>Stomach</b>				
<b>Kidney &amp; Renal Pelvis</b>					Male	1	2.2	nc	(nc-nc)
Male	6	3.6	165.2	(60.3-359.6)	Female	1	1.3	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<b>Testis</b>				
<b>Larynx</b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b>Thyroid</b>				
Female	1	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b>Leukemia</b>					Female	1	2.9	nc	(nc-nc)
Male	6	2.6	229.4	(83.8-499.3)	<b>Uteri Corpus and Uterus, NOS</b>				
Female	1	2.1	nc	(nc-nc)	Female	7	6.6	106.7	(42.8-219.9)
<b>Liver and Intrahepatic Bile Ducts</b>					<b>All Sites / Types</b>				
Male	1	1.8	nc	(nc-nc)	Male	104	115.2	90.3	(73.8-109.4)
Female	0	0.6	nc	(nc-nc)	Female	103	103.8	99.2	(81.0-120.3)
<b>Lung and Bronchus</b>									
Male	11	16.4	67.2	(33.5-120.2)					
Female	16	14.6	109.4	(62.5-177.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## 181 Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b>Bladder, Urinary</b>					<b>Melanoma of Skin</b>				
Male	7	10.1	69.0	(27.6-142.2)	Male	3	6.0	nc	(nc-nc)
Female	7	4.0	175.2	(70.2-361.0)	Female	7	5.4	130.2	(52.2-268.3)

**Brain and Other Nervous System**

Male	4	2.1	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)

**Breast**

Male	0	0.3	nc	(nc-nc)
Female	36	42.1	85.6	(59.9-118.5)

**Cervix Uteri**

Female	3	2.0	nc	(nc-nc)
--------	---	-----	----	---------

**Colon / Rectum**

Male	11	15.4	71.6	(35.7-128.1)
Female	9	15.8	56.9	(26.0-108.0)

**Esophagus**

Male	3	2.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

**Hodgkin Lymphoma**

Male	0	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)

**Kidney & Renal Pelvis**

Male	6	4.5	134.5	(49.1-292.8)
Female	4	3.0	nc	(nc-nc)

**Larynx**

Male	2	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

**Leukemia**

Male	3	3.3	nc	(nc-nc)
Female	5	2.9	172.3	(55.5-402.1)

**Liver and Intrahepatic Bile Ducts**

Male	1	2.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

**Lung and Bronchus**

Male	18	18.9	95.4	(56.5-150.7)
Female	16	19.0	84.2	(48.1-136.7)

**Multiple Myeloma**

Male	1	1.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)

**Non-Hodgkin Lymphoma**

Male	6	5.4	110.3	(40.3-240.0)
Female	11	5.2	210.0	(104.7-375.8)

**Oral Cavity & Pharynx**

Male	4	4.1	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)

**Ovary**

Female	6	4.5	133.5	(48.8-290.6)
--------	---	-----	-------	--------------

**Pancreas**

Male	3	2.9	nc	(nc-nc)
Female	6	3.4	177.9	(65.0-387.3)

**Prostate**

Male	27	39.9	67.6	(44.5-98.4)
------	----	------	------	-------------

**Stomach**

Male	2	2.6	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)

**Testis**

Male	0	1.6	nc	(nc-nc)
------	---	-----	----	---------

**Thyroid**

Male	0	1.3	nc	(nc-nc)
Female	3	4.7	nc	(nc-nc)

**Uteri Corpus and Uterus, NOS**

Female	9	8.6	104.3	(47.6-197.9)
--------	---	-----	-------	--------------

**All Sites / Types**

Male	111	137.3	80.9	(66.5-97.4)
Female	141	140.7	100.2	(84.3-118.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

**Medfield**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				

Male	9	10.4	86.2	(39.3-163.6)	Male	8	6.6	120.6	(51.9-237.7)
Female	1	3.6	nc	(nc-nc)	Female	8	5.4	146.9	(63.2-289.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.9	100.9	(36.9-219.7)
Female	50	44.3	112.9	(83.8-148.8)	Female	2	4.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	6	4.7	126.3	(46.1-275.0)
<b><u>Colon / Rectum</u></b>					Female	2	2.0	nc	(nc-nc)
Male	13	16.2	80.2	(42.6-137.1)	<b><u>Ovary</u></b>				
Female	20	14.2	140.5	(85.8-217.0)	Female	5	4.6	108.7	(35.0-253.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	61	44.4	137.5	(105.1-176.6)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.7	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.6	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.1	137.7	(55.2-283.7)
Male	3	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.9	nc	(nc-nc)	Female	8	8.9	89.6	(38.6-176.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	151	149.1	101.3	(85.8-118.8)
Female	1	0.8	nc	(nc-nc)	Female	155	139.0	111.5	(94.6-130.5)
<b><u>Lung and Bronchus</u></b>									
Male	17	20.2	84.2	(49.0-134.8)					
Female	25	17.8	140.5	(90.9-207.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	68	67.3	101.1	(78.5-128.2)	Male	27	35.3	76.4	(50.4-111.2)
Female	34	27.2	124.9	(86.5-174.6)	Female	24	31.2	76.9	(49.2-114.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	11.7	85.5	(40.9-157.2)	Male	12	10.0	120.6	(62.2-210.7)
Female	9	10.7	83.8	(38.2-159.1)	Female	10	8.6	116.1	(55.6-213.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	33	33.1	99.8	(68.7-140.2)
Female	283	248.0	114.1	(101.2-128.2)	Female	37	34.1	108.4	(76.3-149.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	10.7	56.2	(20.5-122.4)	Male	25	22.7	110.0	(71.2-162.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	105	98.6	106.5	(87.1-128.9)	Female	25	27.3	91.6	(59.3-135.3)
Female	114	108.4	105.1	(86.7-126.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	21	18.5	113.2	(70.1-173.1)
Male	18	16.4	109.9	(65.1-173.6)	Female	16	23.3	68.7	(39.3-111.6)
Female	7	5.3	132.1	(52.9-272.2)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	206	249.4	82.6	(71.7-94.7)
Male	7	5.1	138.3	(55.4-285.0)	<b><u>Stomach</u></b>				
Female	4	4.5	nc	(nc-nc)	Male	19	17.0	111.9	(67.4-174.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	17	11.8	144.1	(83.9-230.7)
Male	19	26.4	72.1	(43.4-112.6)	<b><u>Testis</u></b>				
Female	16	18.7	85.7	(49.0-139.2)	Male	10	8.8	113.9	(54.5-209.4)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	15	10.5	142.8	(79.9-235.5)	Male	5	7.1	70.5	(22.7-164.5)
Female	4	3.2	nc	(nc-nc)	Female	29	24.6	117.8	(78.9-169.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	20.5	97.7	(59.7-150.9)	Female	70	51.4	136.3	(106.3-172.2)
Female	21	18.6	112.8	(69.8-172.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	848	857.9	98.8	(92.3-105.7)
Male	11	12.7	86.8	(43.3-155.3)	Female	925	881.4	104.9	(98.3-111.9)
Female	7	5.4	129.4	(51.8-266.6)					
<b><u>Lung and Bronchus</u></b>									
Male	150	123.5	121.4	(102.8-142.5)					
Female	118	125.8	93.8	(77.6-112.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.7	113.5	(56.6-203.0)	Male	7	6.3	111.5	(44.7-229.7)
Female	5	3.7	135.1	(43.5-315.2)	Female	8	5.6	143.2	(61.7-282.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.6	107.3	(39.2-233.6)
Female	43	42.9	100.3	(72.6-135.1)	Female	4	5.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.2	nc	(nc-nc)	Male	6	4.3	140.1	(51.2-305.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	15.0	106.7	(61.0-173.3)	Female	4	4.5	nc	(nc-nc)
Female	18	14.7	122.4	(72.5-193.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	53	39.8	133.3	(99.8-174.3)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Thyroid</u></b>				
Male	6	4.6	129.8	(47.4-282.5)	Male	2	1.5	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	5	5.3	95.0	(30.6-221.7)
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.7	nc	(nc-nc)	Female	12	8.5	141.6	(73.1-247.3)
Female	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	17	18.5	92.1	(53.6-147.5)
Female	1	3.0	nc	(nc-nc)	Female	20	17.7	113.2	(69.1-174.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	2.3	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

**Melrose**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	32.1	96.5	(65.6-137.0)	Male	23	17.5	131.5	(83.3-197.4)
Female	14	13.1	107.1	(58.5-179.8)	Female	22	15.4	143.3	(89.8-217.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.8	nc	(nc-nc)	Male	5	4.8	103.6	(33.4-241.7)
Female	6	5.3	113.3	(41.4-246.6)	Female	3	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	26	16.1	161.1	(105.2-236.0)
Female	125	123.7	101.0	(84.1-120.4)	Female	12	16.5	72.9	(37.6-127.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.4	nc	(nc-nc)	Male	12	11.6	103.0	(53.2-179.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	56	47.6	117.6	(88.8-152.7)	Female	16	13.5	118.8	(67.8-192.9)
Female	54	52.5	102.9	(77.3-134.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	9.0	77.9	(31.2-160.5)
Male	7	8.0	87.5	(35.1-180.3)	Female	11	11.2	98.2	(49.0-175.7)
Female	3	2.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	157	121.3	129.4	(110.0-151.3)
Male	7	2.3	305.9	(122.5-630.3)	<b><u>Stomach</u></b>				
Female	4	2.0	nc	(nc-nc)	Male	6	8.2	73.5	(26.8-160.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	5.7	104.8	(38.3-228.2)
Male	16	13.1	122.4	(69.9-198.8)	<b><u>Testis</u></b>				
Female	11	9.1	120.9	(60.3-216.3)	Male	2	4.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	12	12.3	97.9	(50.5-171.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	9.9	110.8	(55.3-198.3)	Female	16	25.4	62.9	(35.9-102.1)
Female	5	9.1	55.0	(17.7-128.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	469	416.1	112.7	(102.7-123.4)
Male	5	6.4	78.4	(25.3-182.9)	Female	431	431.3	99.9	(90.7-109.8)
Female	4	2.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	52	58.8	88.4	(66.0-116.0)					
Female	68	60.2	112.9	(87.7-143.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

186

## Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	4.5	nc	(nc-nc)	Male	9	3.0	304.8	(139.1-578.6)
Female	3	1.5	nc	(nc-nc)	Female	5	2.4	207.2	(66.8-483.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	16	18.7	85.3	(48.8-138.6)	Female	3	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	7.0	100.5	(40.3-207.0)	Female	0	1.9	nc	(nc-nc)
Female	5	5.9	84.6	(27.2-197.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	20	18.7	107.1	(65.4-165.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.2	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	13	8.5	153.6	(81.7-262.7)
Female	0	0.3	nc	(nc-nc)	Female	6	7.3	82.4	(30.1-179.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

187

## Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	6.1	131.9	(56.8-259.9)	Male	4	3.6	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	25	23.4	106.7	(69.0-157.5)	Female	3	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	9.2	65.3	(23.8-142.2)	Female	3	2.5	nc	(nc-nc)
Female	13	7.8	167.7	(89.2-286.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	33	24.3	135.7	(93.4-190.6)
Female	0	0.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	1.0	nc	(nc-nc)	Female	7	4.8	146.3	(58.6-301.5)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	90	82.5	109.1	(87.7-134.1)
Female	3	1.5	nc	(nc-nc)	Female	77	75.0	102.6	(81.0-128.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	1	1.3	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	13	11.4	114.5	(60.9-195.8)					
Female	11	10.0	110.0	(54.8-196.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

188

## Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	48.8	114.7	(86.6-148.9)	Male	23	26.7	86.0	(54.5-129.1)
Female	22	19.7	111.9	(70.1-169.4)	Female	15	23.4	64.1	(35.9-105.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	9.2	173.2	(98.9-281.3)	Male	11	7.3	150.1	(74.8-268.6)
Female	6	8.2	73.4	(26.8-159.7)	Female	10	6.3	159.9	(76.5-294.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	20	24.9	80.5	(49.1-124.3)
Female	175	186.3	93.9	(80.5-108.9)	Female	26	25.0	104.0	(67.9-152.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	8.2	85.2	(34.1-175.5)	Male	22	17.5	125.5	(78.6-190.0)
Female					Female	10	9.3	107.8	(51.6-198.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	81	72.5	111.8	(88.8-138.9)	Female	20	20.3	98.4	(60.1-151.9)
Female	85	78.7	108.0	(86.3-133.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	16	13.6	117.3	(67.0-190.5)
Male	10	12.1	82.5	(39.5-151.7)	Female	17	16.8	101.1	(58.9-161.9)
Female	5	3.8	130.3	(42.0-304.2)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	199	181.8	109.4	(94.8-125.7)
Male	6	3.8	156.3	(57.1-340.2)	<b><u>Stomach</u></b>				
Female	3	3.3	nc	(nc-nc)	Male	12	12.4	96.5	(49.8-168.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	8.6	nc	(nc-nc)
Male	24	19.9	120.5	(77.2-179.3)	<b><u>Testis</u></b>				
Female	10	13.8	72.5	(34.7-133.3)	Male	8	6.6	120.7	(52.0-237.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	7.8	89.8	(36.0-184.9)	Male	6	5.6	107.8	(39.4-234.7)
Female	4	2.3	nc	(nc-nc)	Female	17	19.0	89.6	(52.2-143.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	15.5	64.6	(30.9-118.8)	Female	46	38.0	121.0	(88.6-161.4)
Female	16	13.9	115.3	(65.8-187.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	660	632.8	104.3	(96.5-112.6)
Male	8	9.6	83.0	(35.7-163.6)					
Female	4	3.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	78	89.8	86.9	(68.7-108.4)					

Female 94 91.2 103.0 (83.2-126.1)

Female 656 651.2 100.7 (93.2-108.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

189

## Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	17.9	106.3	(63.9-166.0)	Male	13	11.0	118.0	(62.7-201.7)
Female	6	6.8	88.6	(32.3-192.8)	Female	8	9.5	84.3	(36.3-166.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	9.9	130.9	(69.7-223.9)
Female	62	73.3	84.6	(64.9-108.5)	Female	14	9.0	155.3	(84.8-260.6)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	3.6	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	27.5	112.9	(76.7-160.3)	Female	10	7.8	127.6	(61.1-234.7)
Female	25	27.1	92.2	(59.6-136.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male 5 5.2 96.1 (31.0-224.2)				
Male	4	4.8	nc	(nc-nc)	Female 5 5.7 87.1 (28.1-203.4)				
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male 69 71.8 96.1 (74.8-121.6)				
Male	4	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male 5 4.6 107.6 (34.7-251.1)				
<u>Kidney &amp; Renal Pelvis</u>					Female 2 2.9 nc (nc-nc)				
Male	6	8.1	73.8	(26.9-160.5)	<u>Testis</u>				
Female	12	5.1	236.7	(122.1-413.4)	Male 3 3.2 nc (nc-nc)				
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.1	nc	(nc-nc)	Male 1 2.5 nc (nc-nc)				
Female	1	0.9	nc	(nc-nc)	Female 10 8.6 116.9 (56.0-215.1)				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	6.1	nc	(nc-nc)	Female 16 14.9 107.5 (61.4-174.6)				
Female	4	5.1	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	2	4.0	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

**Lung and Bronchus**

Male	44	33.5	131.3	(95.4-176.2)
Female	42	32.0	131.5	(94.7-177.7)

**All Sites / Types**

Male	256	247.4	103.5	(91.2-117.0)
Female	251	243.5	103.1	(90.7-116.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

190

**Middlefield**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	0	2.3	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									

Male	0	0.1	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	5	7.9	63.2	(20.4-147.6)
Female	0	0.9	nc	(nc-nc)	Female	6	6.5	92.1	(33.6-200.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

191

## Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.6	118.6	(54.1-225.2)	Male	5	5.0	99.3	(32.0-231.8)
Female	5	2.5	203.2	(65.5-474.3)	Female	4	3.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.5	156.9	(62.9-323.3)
Female	33	27.6	119.4	(82.2-167.7)	Female	3	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	11.7	68.3	(29.4-134.7)	Female	1	2.9	nc	(nc-nc)
Female	9	9.5	95.0	(43.3-180.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	2.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	30	30.6	98.0	(66.1-139.9)
Male	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.0	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	1.3	372.3	(120.0-868.7)	Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Leukemia</u></b>				
<b><u>Leukemia</u></b>					Male	3	2.7	nc	(nc-nc)

Female	3	1.8	nc	(nc-nc)
--------	---	-----	----	---------

Female	4	3.0	nc	(nc-nc)
--------	---	-----	----	---------

**Liver and Intrahepatic Bile Ducts**

Male	1	1.7	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.5	nc	(nc-nc)
--------	---	-----	----	---------

**Uteri Corpus and Uterus, NOS**

Female	2	5.8	nc	(nc-nc)
--------	---	-----	----	---------

**Lung and Bronchus**

Male	13	14.3	90.6	(48.2-155.0)
------	----	------	------	--------------

Female	16	12.2	131.3	(75.0-213.3)
--------	----	------	-------	--------------

**All Sites / Types**

Male	102	107.6	94.8	(77.3-115.0)
------	-----	-------	------	--------------

Female	95	89.6	106.0	(85.8-129.6)
--------	----	------	-------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

192

**Milford**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	26.5	128.3	(88.8-179.3)	Male	8	15.5	51.6	(22.2-101.7)
Female	5	10.6	47.3	(15.2-110.4)	Female	17	13.6	125.0	(72.8-200.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.5	128.1	(51.3-263.9)	Male	2	4.1	nc	(nc-nc)
Female	7	4.7	149.3	(59.8-307.6)	Female	3	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	15	14.1	106.1	(59.3-175.0)
Female	93	105.9	87.8	(70.9-107.6)	Female	16	13.7	116.8	(66.7-189.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.9	nc	(nc-nc)	Male	8	10.4	77.0	(33.1-151.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	34	40.0	84.9	(58.8-118.7)	Female	10	11.5	87.2	(41.7-160.3)
Female	41	42.6	96.2	(69.0-130.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	7.6	66.1	(21.3-154.3)
Male	8	6.8	117.1	(50.4-230.8)	Female	8	9.0	88.7	(38.2-174.7)
Female	1	2.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	101	102.9	98.2	(79.9-119.3)
Male	0	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	2.0	nc	(nc-nc)	Male	12	6.8	176.1	(90.9-307.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	4.7	129.0	(47.1-280.7)
Male	8	11.5	69.7	(30.0-137.3)	<b><u>Testis</u></b>				
Female	6	7.6	79.2	(28.9-172.4)	Male	3	4.3	nc	(nc-nc)
<b><u>Larynx</u></b>									
Male	3	4.4	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

**Leukemia**

Male	5	8.8	57.1	(18.4-133.2)
Female	4	7.7	nc	(nc-nc)

**Liver and Intrahepatic Bile Ducts**

Male	11	5.6	196.6	(98.0-351.8)
Female	2	2.2	nc	(nc-nc)

**Lung and Bronchus**

Male	55	49.4	111.4	(83.9-145.0)
Female	56	48.9	114.6	(86.5-148.8)

**Thyroid**

Male	3	3.4	nc	(nc-nc)
Female	8	11.6	68.9	(29.7-135.8)

**Uteri Corpus and Uterus, NOS**

Female	20	21.6	92.4	(56.4-142.7)
--------	----	------	------	--------------

**All Sites / Types**

Male	340	356.0	95.5	(85.6-106.2)
Female	345	362.7	95.1	(85.3-105.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

193

**Millbury**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b>Bladder, Urinary</b>					<b>Melanoma of Skin</b>				
Male	12	15.3	78.7	(40.6-137.4)	Male	5	8.4	59.3	(19.1-138.5)
Female	2	6.1	nc	(nc-nc)	Female	2	7.2	nc	(nc-nc)
<b>Brain and Other Nervous System</b>					<b>Multiple Myeloma</b>				
Male	1	2.9	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b>Breast</b>					<b>Non-Hodgkin Lymphoma</b>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.8	64.5	(20.8-150.5)
Female	55	57.9	95.0	(71.6-123.7)	Female	9	7.7	117.3	(53.5-222.8)
<b>Cervix Uteri</b>					<b>Oral Cavity &amp; Pharynx</b>				
Female	3	2.5	nc	(nc-nc)	Male	10	5.7	176.3	(84.4-324.2)
<b>Colon / Rectum</b>					<b>Ovary</b>				
Male	18	22.8	79.0	(46.8-124.9)	Female	6	6.3	95.0	(34.7-206.7)
Female	19	24.3	78.1	(47.0-121.9)	<b>Pancreas</b>				
<b>Esophagus</b>					Male	2	4.3	nc	(nc-nc)
Male	5	3.9	129.3	(41.7-301.8)	Female	3	5.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<b>Prostate</b>				
<b>Hodgkin Lymphoma</b>					Male	58	59.0	98.3	(74.7-127.1)
Male	1	1.1	nc	(nc-nc)	<b>Stomach</b>				
Female	0	1.0	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b>Kidney &amp; Renal Pelvis</b>					Female	1	2.7	nc	(nc-nc)
Male	5	6.3	78.9	(25.4-184.2)	<b>Testis</b>				
Female	5	4.2	117.7	(37.9-274.7)					
<b>Larynx</b>									

Male	5	2.5	199.0	(64.1-464.5)	Male	3	2.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)					
<b><u>Leukemia</u></b>					<b><u>Thyroid</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	5	4.2	118.2	(38.1-275.7)	Female	2	5.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	3.1	nc	(nc-nc)	Female	20	12.0	166.5	(101.7-257.2)
Female	3	1.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	39	28.2	138.5	(98.5-189.3)	Male	192	200.4	95.8	(82.7-110.3)
Female	38	28.2	134.7	(95.3-184.9)	Female	191	201.6	94.7	(81.8-109.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## 194 Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	6.6	182.0	(93.9-318.0)	Male	4	4.3	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	5	3.7	134.2	(43.2-313.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	5	3.8	132.9	(42.8-310.2)
Female	31	29.3	105.8	(71.9-150.2)	Female	2	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
					Female	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	10	10.3	97.4	(46.6-179.2)	Female	3	3.0	nc	(nc-nc)
Female	6	9.2	65.6	(23.9-142.7)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	34	28.5	119.1	(82.5-166.4)
Female	1	0.5	nc	(nc-nc)					
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Stomach</u></b>				
Male	5	3.2	155.9	(50.2-363.7)	Male	2	1.7	nc	(nc-nc)

Female	1	1.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male	2	1.0	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female	3	6.0	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	110	95.2	115.6	(95.0-139.3)
<b><u>Lung and Bronchus</u></b>					Female	92	91.9	100.1	(80.7-122.7)
Male	15	12.8	117.1	(65.5-193.2)					
Female	17	11.9	142.5	(83.0-228.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## 195 Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	1.8	327.1	(119.5-712.0)	Male	2	1.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	10	8.4	119.5	(57.2-219.8)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	5	2.9	174.3	(56.2-406.7)	<b><u>Ovary</u></b>				
Female	1	2.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	7.6	104.8	(45.1-206.6)
Female	0	0.2	nc	(nc-nc)					

**Kidney & Renal Pelvis**

Male	2	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

**Larynx**

Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

**Leukemia**

Male	1	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

**Liver and Intrahepatic Bile Ducts**

Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

**Lung and Bronchus**

Male	6	3.5	169.6	(61.9-369.2)
Female	4	3.5	nc	(nc-nc)

**Stomach**

Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

**Testis**

Male	0	0.5	nc	(nc-nc)
------	---	-----	----	---------

**Thyroid**

Male	0	0.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)

**Uteri Corpus and Uterus, NOS**

Female	5	1.6	305.1	(98.3-711.9)
--------	---	-----	-------	--------------

**All Sites / Types**

Male	38	26.7	142.2	(100.6-195.2)
Female	32	27.1	118.0	(80.7-166.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

196

**Milton**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	30.2	82.7	(53.5-122.0)	Male	34	16.2	209.5	(145.1-292.8)
Female	17	12.1	140.8	(82.0-225.4)	Female	27	14.1	191.7	(126.3-278.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.6	89.8	(28.9-209.6)	Male	4	4.5	nc	(nc-nc)
Female	5	4.9	101.1	(32.6-235.9)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	18	15.1	119.0	(70.5-188.1)
Female	120	115.2	104.1	(86.3-124.5)	Female	24	15.2	157.7	(101.0-234.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	4.9	nc	(nc-nc)	Male	12	10.8	110.9	(57.2-193.7)
					Female	6	5.7	105.1	(38.4-228.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	48	44.7	107.3	(79.1-142.2)	Female	12	12.6	95.6	(49.3-167.0)
Female	57	48.8	116.9	(88.5-151.4)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.5	66.8	(21.5-155.8)	Male	7	8.4	83.1	(33.3-171.2)
Female	2	2.4	nc	(nc-nc)	Female	12	10.4	115.7	(59.7-202.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				

Male	2	2.2	nc	(nc-nc)	Male	117	112.3	104.2	(86.2-124.9)
Female	2	1.9	nc	(nc-nc)					
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Stomach</u></b>				
Male	12	12.2	98.5	(50.8-172.0)	Male	6	7.7	78.1	(28.5-170.0)
Female	11	8.4	130.4	(65.0-233.4)	Female	2	5.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	5	4.8	104.0	(33.5-242.6)	Male	4	3.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)					
<b><u>Leukemia</u></b>					<b><u>Thyroid</u></b>				
Male	9	9.4	95.6	(43.6-181.6)	Male	2	3.3	nc	(nc-nc)
Female	8	8.5	93.9	(40.4-185.0)	Female	15	11.2	133.6	(74.7-220.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	6.0	100.1	(36.6-218.0)	Female	20	23.4	85.4	(52.1-131.9)
Female	3	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	37	55.2	67.0	(47.2-92.4)	Male	378	388.5	97.3	(87.7-107.6)
Female	51	55.5	92.0	(68.5-120.9)	Female	429	399.9	107.3	(97.4-117.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

197

## Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
					Female	0	0.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)

Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	0	1.2	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

198

## Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	8.2	110.1	(50.2-209.0)	Male	8	5.0	159.3	(68.6-313.9)
Female	7	2.9	240.2	(96.2-495.0)	Female	1	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	29	32.7	88.6	(59.3-127.2)	Female	5	3.9	128.4	(41.4-299.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	12.6	87.5	(43.6-156.6)	Female	4	3.5	nc	(nc-nc)
Female	9	11.5	78.4	(35.8-148.8)					

**Esophagus**

Male	1	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

**Hodgkin Lymphoma**

Male	2	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

**Kidney & Renal Pelvis**

Male	1	3.8	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)

**Larynx**

Male	0	1.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

**Leukemia**

Male	1	2.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)

**Liver and Intrahepatic Bile Ducts**

Male	1	1.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

**Lung and Bronchus**

Male	18	15.6	115.4	(68.4-182.4)
Female	9	14.2	63.6	(29.0-120.7)

**Pancreas**

Male	0	2.4	nc	(nc-nc)
Female	6	2.4	245.7	(89.7-534.9)

**Prostate**

Male	31	33.8	91.6	(62.2-130.1)
------	----	------	------	--------------

**Stomach**

Male	2	2.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)

**Testis**

Male	0	1.3	nc	(nc-nc)
------	---	-----	----	---------

**Thyroid**

Male	0	1.1	nc	(nc-nc)
Female	5	3.7	136.2	(43.9-317.9)

**Uteri Corpus and Uterus, NOS**

Female	4	6.7	nc	(nc-nc)
--------	---	-----	----	---------

**All Sites / Types**

Male	94	114.1	82.4	(66.6-100.8)
Female	98	106.5	92.0	(74.7-112.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

199

**Montague**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	9.8	71.1	(28.5-146.5)	Male	5	5.4	92.9	(29.9-216.7)
Female	2	4.0	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.0	120.2	(43.9-261.7)
Female	31	37.7	82.1	(55.8-116.6)	Female	1	5.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	7	3.6	194.3	(77.8-400.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
					Female	3	1.9	nc	(nc-nc)



Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.4	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	6	5.9	101.4	(37.0-220.8)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	21	18.9	111.1	(68.7-169.8)
Male	0	0.3	nc	(nc-nc)	Female	10	14.2	70.7	(33.8-129.9)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	2.7	184.8	(59.5-431.2)					
Female	2	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

201

## Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	6	2.9	205.6	(75.1-447.5)	Female	0	0.3	nc	(nc-nc)

Cervix Uteri

Female	1	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	1	1.2	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.9	nc	(nc-nc)
--------	---	-----	----	---------

Esophagus

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.0	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	1	0.1	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.0	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.2	nc	(nc-nc)
--------	---	-----	----	---------

Larynx

Male	0	0.1	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.0	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	0	0.3	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.2	nc	(nc-nc)
--------	---	-----	----	---------

Liver and Intrahepatic Bile Ducts

Male	1	0.2	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.0	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	2	1.6	nc	(nc-nc)
------	---	-----	----	---------

Female	1	1.2	nc	(nc-nc)
--------	---	-----	----	---------

Oral Cavity & Pharynx

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Ovary

Female	1	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.2	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	3	3.5	nc	(nc-nc)
------	---	-----	----	---------

Stomach

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	1	0.1	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.1	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Uteri Corpus and Uterus, NOS

Female	0	0.6	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	13	11.4	114.5	(60.9-195.8)
------	----	------	-------	--------------

Female	12	9.0	133.6	(69.0-233.4)
--------	----	-----	-------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

202

**Mount Washington**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	0.5	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

203

## Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.8	85.9	(27.7-200.5)	Male	2	3.0	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)

Female	0	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	21	19.0	110.5	(68.4-169.0)	Female	1	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	8	8.6	93.5	(40.3-184.3)	<b><u>Ovary</u></b>				
Female	1	7.8	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	19	21.4	88.6	(53.3-138.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.5	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.8	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.3	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	73	73.2	99.7	(78.2-125.4)
Female	0	0.4	nc	(nc-nc)	Female	60	65.0	92.3	(70.4-118.8)
<b><u>Lung and Bronchus</u></b>									
Male	8	10.5	76.0	(32.7-149.7)					
Female	11	9.1	121.0	(60.3-216.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

204

## Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	8.6	127.5	(63.6-228.2)	Male	15	5.5	271.2	(151.7-447.3)
Female	5	3.1	161.9	(52.2-377.7)	Female	7	4.5	154.7	(62.0-318.7)

**Brain and Other Nervous System**

Male	4	1.9	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)

**Breast**

Male	0	0.3	nc	(nc-nc)
Female	49	33.6	145.9	(107.9-192.9)

**Cervix Uteri**

Female	3	1.7	nc	(nc-nc)
--------	---	-----	----	---------

**Colon / Rectum**

Male	16	13.3	120.7	(69.0-196.1)
Female	19	12.0	157.8	(94.9-246.4)

**Esophagus**

Male	1	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

**Hodgkin Lymphoma**

Male	0	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

**Kidney & Renal Pelvis**

Male	1	4.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)

**Larynx**

Male	0	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

**Leukemia**

Male	1	3.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)

**Liver and Intrahepatic Bile Ducts**

Male	0	1.9	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)

**Lung and Bronchus**

Male	13	16.4	79.1	(42.1-135.3)
Female	11	14.8	74.2	(37.0-132.8)

**Multiple Myeloma**

Male	0	1.4	nc	(nc-nc)
Female	4	1.0	nc	(nc-nc)

**Non-Hodgkin Lymphoma**

Male	5	4.9	101.8	(32.8-237.6)
Female	4	4.1	nc	(nc-nc)

**Oral Cavity & Pharynx**

Male	2	3.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)

**Ovary**

Female	4	3.6	nc	(nc-nc)
--------	---	-----	----	---------

**Pancreas**

Male	2	2.5	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)

**Prostate**

Male	63	35.1	179.7	(138.0-229.9)
------	----	------	-------	---------------

**Stomach**

Male	2	2.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)

**Testis**

Male	3	1.9	nc	(nc-nc)
------	---	-----	----	---------

**Thyroid**

Male	1	1.3	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)

**Uteri Corpus and Uterus, NOS**

Female	2	6.8	nc	(nc-nc)
--------	---	-----	----	---------

**All Sites / Types**

Male	146	121.2	120.5	(101.7-141.7)
Female	133	111.5	119.3	(99.9-141.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

**Natick**

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				

Male	36	35.0	103.0	(72.1-142.6)	Male	36	19.7	182.7	(127.9-252.9)
Female	22	13.8	159.0	(99.6-240.8)	Female	16	17.4	91.7	(52.4-149.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.8	133.0	(60.7-252.5)	Male	6	5.3	113.2	(41.3-246.4)
Female	8	6.0	134.0	(57.7-264.1)	Female	5	4.4	114.2	(36.8-266.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	16	18.0	88.8	(50.7-144.3)
Female	146	138.2	105.6	(89.2-124.2)	Female	16	17.7	90.2	(51.5-146.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	6.3	nc	(nc-nc)	Male	14	13.2	106.4	(58.1-178.5)
<b><u>Colon / Rectum</u></b>					Female	6	6.8	88.8	(32.4-193.2)
Male	55	52.3	105.2	(79.3-137.0)	<b><u>Ovary</u></b>				
Female	54	54.7	98.7	(74.2-128.8)	Female	13	14.9	87.4	(46.5-149.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	8.9	134.4	(69.4-234.8)	Male	7	9.9	70.8	(28.4-145.9)
Female	1	2.7	nc	(nc-nc)	Female	9	11.7	76.9	(35.1-145.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	144	137.6	104.6	(88.3-123.2)
Female	1	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	8.9	90.1	(38.8-177.5)
Male	14	14.8	94.4	(51.6-158.4)	Female	6	5.9	101.6	(37.1-221.1)
Female	11	9.9	110.7	(55.2-198.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	4.9	142.1	(56.9-292.9)
Male	9	5.8	154.6	(70.5-293.5)	<b><u>Thyroid</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	6	4.2	141.4	(51.6-307.7)
<b><u>Leukemia</u></b>					Female	16	14.7	109.1	(62.3-177.1)
Male	12	11.1	107.9	(55.7-188.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	9.8	132.1	(70.3-225.9)	Female	26	28.4	91.5	(59.7-134.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.2	69.7	(22.5-162.7)	Male	483	465.5	103.8	(94.7-113.4)
Female	1	2.8	nc	(nc-nc)	Female	483	471.3	102.5	(93.5-112.0)
<b><u>Lung and Bronchus</u></b>									
Male	60	65.6	91.5	(69.8-117.8)					
Female	80	65.1	123.0	(97.5-153.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	36.9	89.4	(61.6-125.6)	Male	26	19.3	134.6	(87.9-197.3)
Female	15	15.0	100.2	(56.0-165.2)	Female	18	16.4	109.6	(64.9-173.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	6.5	169.4	(84.4-303.1)	Male	3	5.5	nc	(nc-nc)
Female	8	5.8	137.6	(59.3-271.2)	Female	7	4.7	149.0	(59.7-307.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	13	18.0	72.0	(38.3-123.2)
Female	165	136.3	121.1	(103.3-141.0)	Female	28	18.5	151.7	(100.8-219.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.6	nc	(nc-nc)	Male	8	12.9	62.0	(26.7-122.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	49	54.4	90.1	(66.7-119.1)	Female	14	14.9	93.7	(51.2-157.2)
Female	56	61.2	91.5	(69.1-118.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	10.3	97.6	(46.7-179.4)
Male	4	9.1	nc	(nc-nc)	Female	16	13.0	123.4	(70.5-200.5)
Female	3	2.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	161	136.4	118.0	(100.5-137.7)
Male	3	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	4	9.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	6.8	nc	(nc-nc)
Male	15	14.6	102.5	(57.3-169.0)	<b><u>Testis</u></b>				
Female	10	10.1	99.3	(47.5-182.5)	Male	4	3.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	5.8	nc	(nc-nc)	Male	9	3.8	239.8	(109.4-455.2)
Female	1	1.7	nc	(nc-nc)	Female	12	12.5	96.1	(49.6-167.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	11.2	89.0	(42.6-163.6)	Female	21	27.9	75.2	(46.5-115.0)
Female	12	10.4	115.0	(59.4-201.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	447	469.1	95.3	(86.7-104.5)
Male	6	7.1	84.0	(30.7-182.9)	Female	509	481.7	105.7	(96.7-115.3)
Female	4	3.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	48	67.0	71.6	(52.8-94.9)					
Female	62	66.7	92.9	(71.2-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	3	1.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	5	3.3	151.3	(48.8-353.2)
Male	0	0.1	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	0	0.5	nc	(nc-nc)					
Female	1	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	112	105.7	106.0	(87.3-127.5)	Male	20	56.0	35.7	(21.8-55.2)
Female	39	44.1	88.5	(62.9-121.0)	Female	28	50.1	55.9	(37.1-80.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	25	19.3	129.7	(83.9-191.5)	Male	17	15.7	108.3	(63.1-173.5)
Female	13	17.8	73.2	(39.0-125.2)	Female	17	14.0	121.9	(70.9-195.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	38	52.4	72.5	(51.3-99.5)
Female	337	397.2	84.9	(76.0-94.4)	Female	41	55.3	74.2	(53.2-100.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	17.1	105.6	(62.5-166.9)	Male	37	36.3	102.0	(71.8-140.6)
Female					Female	21	20.3	103.5	(64.0-158.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	146	155.4	94.0	(79.3-110.5)	Female	50	43.9	113.9	(84.5-150.1)
Female	167	176.3	94.7	(80.9-110.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	35	29.2	119.7	(83.3-166.4)
Male	25	25.8	96.7	(62.6-142.8)	Female	47	37.8	124.4	(91.4-165.4)
Female	6	8.6	69.9	(25.5-152.1)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	374	391.8	95.4	(86.0-105.6)
Male	8	8.2	97.7	(42.1-192.5)	<b><u>Stomach</u></b>				
Female	13	7.4	175.6	(93.4-300.3)	Male	47	26.7	175.7	(129.1-233.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	31	19.2	161.1	(109.4-228.6)
Male	51	41.8	122.1	(90.9-160.5)	<b><u>Testis</u></b>				
Female	38	30.2	125.9	(89.1-172.8)	Male	13	13.9	93.9	(49.9-160.5)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	20	16.6	120.6	(73.6-186.2)	Male	12	11.3	106.3	(54.9-185.8)
Female	4	5.1	nc	(nc-nc)	Female	25	39.4	63.5	(41.1-93.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	44	33.1	133.0	(96.6-178.5)	Female	94	82.1	114.5	(92.6-140.2)
Female	29	30.8	94.2	(63.1-135.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	1375	1353.7	101.6	(96.3-107.1)
Male	36	20.1	178.7	(125.1-247.4)	Female	1321	1421.9	92.9	(88.0-98.1)
Female	12	8.8	136.7	(70.5-238.8)					
<b><u>Lung and Bronchus</u></b>									
Male	230	193.5	118.9	(104.0-135.2)					
Female	183	202.6	90.3	(77.7-104.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

209

## New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.2	185.3	(67.7-403.3)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Female</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	12	11.6	103.7	(53.5-181.2)
Female	0	0.2	nc	(nc-nc)	Female	8	11.0	72.6	(31.2-143.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Male</u></b>				
Male	0	0.2	nc	(nc-nc)	<b><u>Female</u></b>				
Female	1	0.1	nc	(nc-nc)	<b><u>Male</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Female</u></b>				
Male	1	1.5	nc	(nc-nc)	<b><u>Male</u></b>				
Female	1	1.4	nc	(nc-nc)	<b><u>Female</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

210

## New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	3.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.5	nc	(nc-nc)	0	0.6	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)	Female				
<b><u>Hodgkin Lymphoma</u></b>					1				
Male	0	0.1	nc	(nc-nc)	0.5	nc	(nc-nc)		
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.9	nc	(nc-nc)	3	8.2	nc	(nc-nc)	
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Larynx</u></b>					Male				
Male	1	0.3	nc	(nc-nc)	0	0.5	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)	Female				
<b><u>Leukemia</u></b>					0				
Male	0	0.6	nc	(nc-nc)	0.2	nc	(nc-nc)		
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male				
Male	1	0.4	nc	(nc-nc)	0	0.2	nc	(nc-nc)	
Female	1	0.1	nc	(nc-nc)	Female				
<b><u>Lung and Bronchus</u></b>					1				
Male	0	3.8	nc	(nc-nc)	0.6	nc	(nc-nc)		
Female	2	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>All Sites / Types</u></b>					Male				
					10	27.1	37.0	(17.7-68.0)	
					Female				
					17	20.6	82.6	(48.1-132.2)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

211

## New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	5	4.7	106.6	(34.4-248.8)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	14	15.5	90.6	(49.5-151.9)
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	3	2.1	nc	(nc-nc)					

Female	1	1.5	nc	(nc-nc)	Female	10	11.9	84.2	(40.3-154.9)
--------	---	-----	----	---------	--------	----	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;